• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis.

作者信息

Kidogawa Moe, Yamasaki Kei, Nemoto Kazuki, Yatera Kazuhiro

机构信息

Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan.

出版信息

Intern Med. 2022 Aug 15;61(16):2547-2549. doi: 10.2169/internalmedicine.8796-21. Epub 2022 Feb 1.

DOI:10.2169/internalmedicine.8796-21
PMID:35110485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9449627/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/6529f1dbb3c3/1349-7235-61-2547-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/1bfb9ba22dce/1349-7235-61-2547-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/885f64f0b918/1349-7235-61-2547-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/6529f1dbb3c3/1349-7235-61-2547-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/1bfb9ba22dce/1349-7235-61-2547-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/885f64f0b918/1349-7235-61-2547-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2aa/9449627/6529f1dbb3c3/1349-7235-61-2547-g003.jpg

相似文献

1
Liposomal Amikacin Inhalation Suspension-induced Pneumonitis.脂质体阿米卡星吸入混悬液诱发的肺炎
Intern Med. 2022 Aug 15;61(16):2547-2549. doi: 10.2169/internalmedicine.8796-21. Epub 2022 Feb 1.
2
A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.阿米卡星脂质体吸入混悬液致药物性机化性肺炎 1 例
J Infect Chemother. 2023 Aug;29(8):806-808. doi: 10.1016/j.jiac.2023.04.013. Epub 2023 Apr 23.
3
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.硫酸卷曲霉素脂质体吸入混悬液治疗鸟分枝杆菌复合体肺病的研究进展
Drugs. 2019 Apr;79(5):555-562. doi: 10.1007/s40265-019-01095-z.
4
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.卷曲霉素脂质体吸入混悬液治疗难治性鸟分枝杆菌复合群肺病：使用情况概述。
Clin Drug Investig. 2021 Apr;41(4):405-412. doi: 10.1007/s40261-021-01010-z. Epub 2021 Mar 16.
5
Amikacin Liposome Inhalation Suspension for Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial.阿米卡星脂质体吸入混悬液治疗复杂肺部疾病：一项为期 12 个月的开放性标签扩展临床试验。
Ann Am Thorac Soc. 2021 Jul;18(7):1147-1157. doi: 10.1513/AnnalsATS.202008-925OC.
6
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂（CONVERT）引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
7
New Antibiotic Approved for Refractory Mycobacterium Avium Complex.新型抗生素获批用于治疗难治性鸟分枝杆菌复合群感染
Am J Nurs. 2019 Jan;119(1):26. doi: 10.1097/01.NAJ.0000552604.35664.f5.
8
Management of dysphonia caused by amikacin liposome inhalation in complex pulmonary disease.阿米卡星脂质体吸入治疗复杂肺部疾病所致发音障碍的管理
Int J Tuberc Lung Dis. 2023 Aug 1;27(11):872-873. doi: 10.5588/ijtld.23.0275.
9
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.阿米卡星脂质体吸入混悬液治疗难治性鸟分枝杆菌复合群肺病：培养转换的可持续性和耐久性及长期暴露的安全性。
Chest. 2021 Sep;160(3):831-842. doi: 10.1016/j.chest.2021.03.070. Epub 2021 Apr 19.
10
Acquisition of Amikacin Resistance during Amikacin Liposome Inhalation Suspension Add-on Therapy for Complex Pulmonary Disease.在阿米卡星脂质体吸入混悬液辅助治疗复杂肺部疾病期间获得阿米卡星耐药性。
Ann Am Thorac Soc. 2024 Mar;21(3):526-529. doi: 10.1513/AnnalsATS.202305-454RL.

引用本文的文献

1
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.起始治疗 6 个月后，卷曲霉素脂质体吸入混悬液治疗耐多药鸟分枝杆菌复合群肺病的疗效。
BMC Pulm Med. 2024 Sep 10;24(1):442. doi: 10.1186/s12890-024-03261-w.
2
Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Complex Pulmonary Disease: A Case Report.难治性复杂肺部疾病中与阿米卡星脂质体吸入混悬液相关的药物性间质性肺疾病的诊断与管理：一例报告
Infect Drug Resist. 2023 Oct 10;16:6629-6634. doi: 10.2147/IDR.S427544. eCollection 2023.
3

本文引用的文献

1
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂（CONVERT）引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Complex Lung Disease in Real-World Settings.
现实环境中脂质体阿米卡星吸入治疗难治性复杂肺部疾病的早期不良反应及管理
Infect Drug Resist. 2022 Jul 26;15:4001-4011. doi: 10.2147/IDR.S373783. eCollection 2022.